Chinese Adults With Kidney Disease | MicrobiomeTrials← Back to trialsNCT07522099
Chinese Adults With Kidney Disease
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-05-21Est. Completion: 2028-07-10
Enrollment target: 30 participants Locations- ADARx Clinical Site, Shenzhen, Guangdong, China
- ADARx Clinical Site, Guiyang, Guizhou, China
- ADARx Clinical Site, Zhengzhou, Henan, China
- ADARx Clinical Site, Baotou, Inner Mongolia, China
- ADARx Clinical Site, Wuxi, Jiangsu, China
- ADARx Clinical Site, Yantai, Shandong, China
- ADARx Clinical Site, Beijing, China
- ADARx Clinical Site, Shandong, China
- ADARx Clinical Site, Shanghai, China
Other microbiome trials you might be interested in
Primary Immunoglobulin A Nephropathy (IgAN)
The study is an open-label, single arm, multicenter, Phase III study to determine proteinuria reduction, pharmacokinetic…
Madera, United StatesEst. completion Jun 28, 2030
Immunoglobulin A (IgA) Nephropathy
The purpose of the study is to evaluate safety, tolerability, and preliminary effectiveness following administration of …
Miami, United StatesEst. completion Sep 2028
Phase 3
Recruiting
Immunoglobulin A Nephropathy
The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of povetacicept in participants…
Multiple LocationsEst. completion Dec 28, 2029